Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin induction, radiotherapy, and tegafur/gimeracil/oteracil adjuvant therapy in N3M0 nasopharyngeal carcinoma
ChiCTR2100041804Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2021
- Modality
- Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and tegafur + gimeracil + oteracil in nasopharyngeal carcinoma (NPC), sponsored by Minghui Pharmaceutical, Inc. Primary endpoint: Distant metastasis-free survival (DMFS). Started Jan 2021; status: recruiting.
02
Drugs
gemcitabinecisplatintegafur + gimeracil + oteracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100041804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041804.